Τίτλος:
Clinical features and outcomes of hospitalized COVID-19 patients in a low burden region
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Data on the clinical features and outcomes of COVID-19 patients from countries with low disease burden are rare. Greece, however, presented a low burden of COVID-19 disease during the first pandemic outbreak. This is a retrospective study of COVID-19 hospitalized patients in Greece. Clinical data were extracted from medical records using univariable and multivariable logistic regression analyses to assess the factors associated with Intensive Care Unit (ICU) admission and in-hospital death. Eighty-five patients were included in this study, 49 (57.7%) male with median (25th-75th) age 60 (49–72) years old. Sixty-one (72%) of them had at least one comorbidity with hypertension being the most common (45,6%). More than half (56%) had severe or critical disease, 20% required ICU care (14% received invasive ventilation) and 10.7% died. Solid tumor (p = 0.021) and NEWS score (p = 0.048), thrombocytopenia (p = 0.036) or involvement of all lung fields in chest x-ray (p = 0.002) on admission were independent risk factors for ICU admission. Immunosuppression (p = 0.032) and thrombocytopenia (p = 0.049) were independent predictors of death. Hospitalized COVID-19 patients in a European country with a low burden of the disease, in which hospital capacities had not been overwhelmed, had lower mortality rate compared to those reported for patients hospitalized in regions with a high burden of the disease. © 2021 Informa UK Limited, trading as Taylor & Francis Group.
Συγγραφείς:
Eleni, M.
Evangelia, M.
Eleftheria, K.
Vasilios, V.
Vana, S.
Vissaria, S.
Evangelos, B.
Ioannis, K.
Περιοδικό:
Pathogens and Global Health
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
alanine aminotransferase; alkaline phosphatase; aspartate aminotransferase; azithromycin; C reactive protein; calcium; colchicine; convalescent plasma; creatine kinase; creatinine; D dimer; ferritin; fibrinogen; gamma glutamyltransferase; glucose; hydroxychloroquine; lactate dehydrogenase; potassium; remdesivir; sodium; steroid; troponin; adenosine phosphate; alanine; antiinfective agent; antimalarial agent; antivirus agent; azithromycin; colchicine; corticosteroid; hydroxychloroquine; remdesivir, acute heart infarction; adult; aged; ageusia; anosmia; anticoagulant therapy; Article; artificial ventilation; blood cell count; body temperature; breathing rate; chronic kidney failure; chronic obstructive lung disease; clinical feature; clinical outcome; computer assisted tomography; coronary artery disease; coronavirus disease 2019; coughing; diabetes mellitus; diarrhea; disease burden; disease exacerbation; disease severity; dyspnea; erythrocyte sedimentation rate; fatigue; female; fever; ground glass opacity; headache; heart rate; hematologic malignancy; high flow nasal cannula therapy; Horowitz index; hospital admission; hospital patient; human; hypertension; hypoxemic respiratory failure; immunosuppressive treatment; in-hospital mortality; intensive care unit; invasive ventilation; lung ultrasound score; lymphocyte count; major clinical study; male; mortality rate; myalgia; nasopharyngeal swab; National Early Warning Score; nose obstruction; observational study; percutaneous coronary intervention; platelet count; quadriplegia; real time reverse transcription polymerase chain reaction; renal replacement therapy; respiratory failure; retrospective study; risk factor; Severe acute respiratory syndrome coronavirus 2; solid malignant neoplasm; sore throat; systolic blood pressure; thorax pain; thorax radiography; thrombocytopenia; thrombosis prevention; vomiting; combination drug therapy; epidemiology; Greece; hospitalization; middle aged; pathology; therapy; treatment outcome; young adult, Adenosine Monophosphate; Adrenal Cortex Hormones; Adult; Aged; Alanine; Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Colchicine; COVID-19; Drug Therapy, Combination; Female; Greece; Hospitalization; Humans; Hydroxychloroquine; Male; Middle Aged; Retrospective Studies; SARS-CoV-2; Treatment Outcome; Young Adult
DOI:
10.1080/20477724.2021.1893485
